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Abstract: Alzheimer’s disease (AD) is a neurodegenerative disease, characterized histopathologically
by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in the brain
parenchyma and around cerebral blood vessels. According to the vascular hypothesis of AD, an
alteration in the neurovascular unit (NVU) could lead to Aβ vascular accumulation and promote
neuronal dysfunction, accelerating neurodegeneration and dementia. To date, the effects of insoluble
vascular Aβ deposits on the NVU and the blood–brain barrier (BBB) are unknown. In this study,
we analyze different Aβ species and their association with the cells that make up the NVU. We
evaluated post-mortem AD brain tissue. Multiple immunofluorescence assays were performed
against different species of Aβ and the main elements that constitute the NVU. Our results showed
that there are insoluble vascular deposits of both full-length and truncated Aβ species. Besides,
insoluble aggregates are associated with a decrease in the phenotype of the cellular components that
constitute the NVU and with BBB disruption. This approach could help identify new therapeutic
targets against key molecules and receptors in the NVU that can prevent the accumulation of vascular
fibrillar Aβ in AD.
Keywords: Alzheimer’s disease; fibrillar amyloid; pyroglutamate-modified amyloid-beta peptides;
neurovascular unit; blood–brain barrier; caspase-5
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1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by
memory impairment and cognitive and functional decline. Neuropathological hallmarks
of AD include the intra-neuronal tau-related lesions and the accumulation of amyloid β-
peptide (Aβ) in the brain parenchyma, in the form of neuritic plaques (NPs), and cerebral
blood vessels as cerebral amyloid angiopathy (CAA). Furthermore, the disruption of the
neurovascular unit (NVU) has been linked to AD and other neurodegenerative diseases [1].
The two-hit vascular hypothesis of AD states that vascular risk factors (hit 1) lead
to the dysfunction of the blood–brain barrier (BBB) and the NVU, initiating a cascade of
events that precedes dementia. The cerebrovascular damage reduces Aβ clearance at the
BBB and increases its production by cleaving amyloid-β precursor protein (APP), leading
to Aβ accumulation (hit 2) [2].
The main Aβ variants detected in the human brain are Aβ1-40 and Aβ1-42. However, a
significant proportion of Aβ in AD brain consists also of N-terminally truncated species [3].
AβN3(pE) and AβN11(pE), Aβ peptides, including N-terminal pyroglutamate at positions
3 and 11, have been demonstrated to be a major N-terminal truncated constituent of
intracellular and extracellular deposits in AD brain [4–6]. Diffuse amyloid plaques, one
of the earliest forms of amyloid deposits, have also been shown to contain AβN3(pE) [7].
Pyroglutamate-containing Aβ species show an increased aggregation propensity and
have been proposed to play an important role during the initiation of the disease, even
before the onset of clinical symptoms [4]. It has been proposed that Aβ molecules tend to
aggregate and form oligomers, protofibrils, and finally mature fibrils, triggering neuronal
dysfunction (directly affecting the synapse or indirectly promoting glial activation) [8–10].
In the last decade, the oligomer hypothesis was postulated, in which it is suggested that
Aβ oligomers may initiate the cascade of neuropathological events in AD [11]. The Aβ
oligomers are soluble and may spread throughout the brain, being considered the most
toxic Aβ form [11]. Amyloid fibrils are larger and insoluble, and assemble into NPs, being
recognized by thiazine red (TR) [12–14].
Alterations in the NVU compromises the brain microcirculation and vascular neuroin-
flammatory responses [15]. The NVU, or the minimal functional unit of the brain, includes
vascular cells, glial cells, neurons, and endothelial cells [16–18], with the latter present
in the BBB. The BBB is a specialized structure in the cerebral vasculature, which limits
the entry of toxic agents, pathogens, and cells into the brain[19]. It has been postulated
that deposition of Aβ in the vessels can alter the NVU and promote or exacerbate AD by
triggering several pathological events, such as neuroinflammation, chronic hypoperfusion,
and ischemia [20–22]. However, the species of Aβ that are deposited on the walls of the
cerebral vessels have not been fully elucidated.
Thus, this work aimed to demonstrate the association between different Aβ species
and NVU disruption in sporadic AD brains. Our results demonstrate that the amyloid
peptides Aβ1-40 and AβN3 (pE) are the major species that are deposited as fibrils on the
walls of blood vessels. Interestingly, these insoluble deposits are related to a phenotypic
loss of pericytes, vessel-associated microglia, and astrocytic end-foot processes, as well as
with the breakdown of tight junctions.
2. Results
2.1. Distinct Deposition of Aβ Species in Blood Vessel Walls of AD Brains
Different species of Aβ have been described in AD brains [23]. To analyze the forms of
Aβ that are present in the walls of the cerebral vessels, we carried out immunofluorescent
staining for the full-length Aβ species (Aβ1-40 and Aβ1-42), the N-truncated/modified Aβ
species (AβN3 [24] and AβN11 [pE]), and for fibrillar, thiazin red (TR)-positive Aβ deposits.
All the Aβ forms studied were found in blood vessel walls (Figure 1). Interestingly, the
aggregation pattern showed distinct patterns of reactivity. While AβN3 [pE] and Aβ1-40
deposits were found along the entire vessel wall (Figure 1A–C), Aβ1-42 immunoreactivity
showed a patchy distribution along the vessel axis (Figure 1C). A diffuse immunoreactivity
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for truncated peptide AβN11 [pE] was observed around the vessel (Figure 1D). String ves-
sels (Figure 1A, blue arrowheads) and structural alterations (Figure 1B, white arrowheads)
positive only for AβN3 [pE] were detected in the blood vessels in AD brains.
Figure 1. Double and triple immunofluorescence analysis of Alzheimer’s disease (AD) brains for
the simultaneous detection of fibrillar Aβ species on blood vessel walls (V). (A) Representative
micrograph sections of insoluble (stained with thiazine red (TR); red channel), AβN3(pE) peptide
(green channel) and Aβ1-40 (blue) deposits that span the entire vessel wall, with blue arrowheads
pointing to suspected string vessels. (B) Triple immunostaining against AβN3(pE) peptide (green),
TR (red), and Aβ1-42 (blue); the amyloid deposits are observed both in the amyloid plaque (P) and in
the wall of the blood vessel (V), and, for the latter, structural alterations are observed (arrowhead).
(C) Representative micrograph of dense, insoluble (TR; red channel) Aβ1-40 (blue channel) deposits
and patchy deposits of Aβ1-42 (green channel, white arrows), on the blood-vessel wall. (D) Repre-
sentative micrograph of dense, insoluble amyloid deposits (TR; red channel) and diffuse perivascular
and blood vessel wall deposits of AβN11(pE) (green channel). The scale bar = 20 µm is common for
all micrographs.
2.2. Extracellular, Vascular, and Intracellular Amyloid Deposits Trigger Morphological Changes
in Microglia
Proliferation and activation of microglia in the brain are prominent AD features [25].
We observed activated microglia closely associated with amyloid plaques (Figure 2A,B;
white arrowheads) in AD. These microglia were found around AβN3 [pE] plaque and
fibrillar TR-positive plaque. Microglia exhibited an intimate interaction of their processes
with Aβ. Microglia showed a thickening of their processes (Figure 2A,B; blue arrowheads),
to develop an amoeboid-like morphology (Figure 2A,B; purple arrowheads). Nuclear
condensation (Figure 2B; red arrowheads) was observed by using TO-PRO®-3 dye.
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Figure 2. Representative micrographs of double and triple immunostainings of microglia in AD
brains. (A) Microglia (green channel) surrounding (white arrowheads) an amyloid plaque (P)
with AβN3(pE) peptide deposits (red channel). (B) Microglia (green channel) surrounding (white
arrowheads) a fibrillar TR-positive amyloid plaque (P; red channel). Changes in the morphology
(purple arrowheads) of microglia ramifications (blue arrowheads) and the nuclear morphology (blue
channel; red arrowheads) are indicated in both panels. Control (C) and AD (D) brains show vessel
(V)-associated microglia (yellow arrowheads; green channel) counterstained with TR (red channel).
(E,F) Representative micrographs of microglia (white arrowheads; green channels) surrounding a
neurofibrillary tangle (NFT) (white arrow; red channel) and Aβ (+) cells (red channel), respectively.
Some tissues were counterstained with TO-PRO®-3 (blue channel). The scale bar = 20 µm.
On the other hand, vessel-associated microglia (Figure 2C,D), showed a different
distribution pattern in control and AD brains. In control brains (Figure 2C), continuity
was observed in the microglia cells along the blood vessel (Figure 2C; yellow arrowheads).
In AD (Figure 2D), an apparent decrease in immunostaining for microglia was noticed.
Furthermore, these microglia did not show continuity throughout the TR-positive vessel
(Figure 2D; yellow arrowheads).
Interestingly, microglial cells were also found to be associated with TR-positive neu-
rofibrillary tangles (NFTs) (Figure 2E; white arrowheads). In this case, microglia exhibited a
resting morphology. Dystrophic microglia were found around Aβ-positive-cells (Figure 2F;
white arrowheads). Soluble oligomers of AβN3 [pE] were found intracellularly.
2.3. Fibrillar Amyloid Deposits in the Cerebral Vasculature Trigger Morphological Changes in
Astrocytic End-Foot Processes
Previous studies have shown the presence of astrocytes surrounding NPs [26]. Con-
sistently, we observed astrocytes surrounding the NPs (Figure 3A–C). Interestingly, we
observed a greater level of astrocyte associated with Aβ1-42 fibrillar amyloid plaques than
with diffuse plaques (Figure 3A–C, white arrows).
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Figure 3. Representative micrographs of triple and quadruple immunostainings for astrocytes in
AD brains. (A–C) Representative images of triple immunostaining against Aβ1-42 (green channels),
TR (red channels), and glial fibrillary acidic protein (GFAP) (blue channels), showing how the
astrocytes surround (white arrowheads) the amyloid plaques (P), both in a panoramic view (A)
and in closer detail (B,C). (D) Representative micrograph of an NFT that was labeled, using TG3
(green channel) and TR (red channel), surrounded by astrocytes (blue channel). (E–G) Astrocytic
end-foot processes (white arrowheads) around the blood vessels (V) are shown. (E) Control brain
and (F) AD brain, after quadruple immunostaining for GFAP (green channels), TR (red channels),
Aβ1-40 (blue channels), and DAPI (4′,6-diamidino-2-phenylindole) nuclear counterstain (yellow
channels). (G) Triple immunostaining against Aβ1-42 (green channel), TR (red channel), and GFAP
(blue channel). The scale bars = 100µm for the panoramic view (a) and 20µm for others.
Importantly, astrocytes in the vicinity of the TR-positive NFTs were noticed (Figure 3D).
Some of these astrocytes appeared intermixed with the tau filaments that make up the
NFTs. Moreover, TG3-positive tau was seen in the vicinity of the NFTs. In Figure 3E–G,
astrocytic end-foot processes in AD and control brains are shown. These end-foot pro-
cesses were thicker and more abundant in control brains (white arrowheads; Figure 3E),
compared to AD brains (white arrowheads; Figure 3F,G). Astrocytic end-foot processes ap-
peared much thinner when associated with insoluble vascular amyloid deposits (Figure 3G,
white arrowheads).
2.4. The α-Smooth Muscle Actin Is Fundamentally Associated with Soluble Aβ Deposits in AD
Pericytes are a component of the NVU and play a crucial role in regulating cerebral
blood flow when they contract [27]. Several studies have demonstrated that most capillary
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pericytes in the central nervous system contained little or no α -SMA expression, a key
protein for their contraction [28–30]. Thus, in order to analyze the possible damage of the
microvasculature, we investigated α-SMA reactivity.
We found expression of α-SMA in AD (Figure 4) but not in control brains (data not
shown). The α-SMA immunoreactivity was observed throughout the cerebral vasculature
(Figure 4A–D). Interestingly, expression of α-SMA was greater in those areas that were
devoid of Aβ immunoreactivity (Figure 4A–D; yellow arrowheads) than insoluble deposits
(Figure 4A–D; white arrowheads).
Figure 4. Representative micrographs of triple immunostainings for α-SMA-positive pericytes in
AD brains. (A,B) Immunostaining for pericytes (green channels), TR (red channels), and contrast
with TO-PRO®-3 (blue channels). (C,D) Immunostaining for pericytes (green channels), TR (red
channels), and deposits of Aβ1-40 and AβN3(pE) (blue channels). Extensive (yellow arrowheads)
and occasional (white arrowheads) immunoreactivity for pericytes along the blood vessel (V) is
observed in all panels. The scale bars = 60µm for (A,B), 100µm for (C), and 40 µm for (D).
2.5. Disruption of the Tight-Junction Integrity in the Cerebral Vessels in AD Brains
Previous studies have suggested significant BBB alterations in both vascular and
degenerative forms of dementia. Tight junctions (TJs) are major components of the BBB that
physically obstruct the inter-endothelial space and restrict blood-borne substances from the
peripheral circulation to the CNS [31]. Claudin-5 (Cl-5) is one of the proteins involved in
TJs. It is expected that the “sealing role” of TJs and Cl-5 is altered in pathological situations.
Thus, we performed immunofluorescent staining with antibodies against Cl-5, to analyze
the integrity of TJs and brain microvasculature.
We observed a notable increase in the expression of Cl-5 in AD, compared to the
control brains (Figure 5A,B). Cl-5 presented a characteristic expression of continuity and
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well-defined borders in the microvasculature of control brains (Figure 5C, red arrowheads).
However, Cl-5 showed a fragmented pattern with undefined edges (Figure 5D,E, white
arrowheads) in AD. Moreover, Cl-5 remnants (dotted pattern) were observed in the vicinity
of the fibrillar amyloid plaques (Figure 5E,F), due to disruption of TJs.
Figure 5. Double and triple immunofluorescent staining of tight junctions in AD and control brains.
Representative panoramic views of control (A) and AD (B) brains with double immunostaining
for claudin- 5 (Cl-5; green channels) and TR (red channels). (C–F) Representative images of triple
immunostaining in control (C) and AD (D–F) brains, for Cl-5 (green channels), TR (red channels),
and TO-PRO®-3 (blue channels). Continuity (red arrowheads) and discontinuity (white arrowheads)
of the tight junctions are indicated. The scale bars = 100 µm for the panoramic views (A,B) and 20µm
for magnifications (C–F).
2.6. Activated Caspase-5 Is Expressed in Blood Vessels of AD Brains
In AD, an inflammatory environment surrounds the cerebral microvasculature, fa-
vored by the accumulation of Aβ, and associated with NVU dysfunction [32]. Caspase-5 is
an enzyme belonging to the family of inflammatory caspases [33], which, under physiolog-
ical conditions, is expressed at very low levels in the brain [34]. We observed the presence
of caspase-5 in AD brains (Figure 6). Specifically, caspase-5 was present extensively in
the cerebral vasculature in AD (Figure 6), but was not present in healthy brains (data not
shown). To our knowledge, we are the first group to report the presence of this caspase in
the AD brain. Interestingly, caspase-5 was expressed in greater levels in those areas that
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were devoid of Aβ immunoreactivity in the blood vessel (Figure 6B,C; white arrowheads),
as compared with insoluble amyloid deposits (Figure 6A–C). We also observed that amy-
loid deposits were also present in the vessel lumen (Figure 6D; purple arrowhead) and in
pathological tau surrounding the cerebral vasculature (Figure 6D; yellow arrowheads) in
AD brains.
Figure 6. Representative micrographs of caspase-5 immunoreactivity in the blood vessels (V) of
AD brains. (A) Immunostaining for caspase-5 (green channel), TR (red channel), and TO-PRO®-3
(blue channel). (B,C) Triple immunostaining against caspase-5 (green channel) TR (red channel),
Aβ1-40 (panel B; blue channel), and AβN3(pE) peptide (C) (blue channel). (D) Three-dimensional
(3D) reconstruction from several stacks of laser scanning confocal microscopy images of a blood
vessel (V) immunoreactive for caspase-5 (green channel), surrounding pathological tau (red chan-
nel; yellow arrowheads), and Aβ1-40 deposits (blue channel) on a plaque (P), as in the lumen of
the blood vessel (purple arrowhead). The soluble Aβ vascular deposits are associated with exten-
sive immunoreactivity for caspase-5 (white arrowheads). The scale bar = 20 µm is common for
all micrographs.
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3. Discussion
Neuropathological hallmarks of AD are the NFTs, the accumulation of Aβ in the
brain parenchyma and around cerebral blood vessels (cerebral amyloid angiopathy; CAA),
and NVU dysfunction [1]. The NVU consists of different cell types, including vascular
cells such as (1) brain endothelial cells lining the cerebral vascular tree, pericytes covering
microvascular capillaries, and vascular smooth muscle cells (VSMCs) enwrapping cerebral
arterioles and arteries; (2) glial cells, such as vessel-associated microglia, astrocytic end-foot
processes, and oligodendrocytes; and (3) neurons. The NVU includes the different cell
types involved in the formation of the BBB [1,16,17,24]. CAA is almost universally found
in AD patients [35]. However, the specific Aβ species associated with blood vessels have
not been fully elucidated. In this work, we analyzed Aβ1-40, Aβ1-42, and N-truncated
peptides like AβN3 (pE) and AβN11 (pE) deposition in the wall of blood vessels. These
peptides are cytotoxic and the principal markers in AD.
We observed extensive immunoreactivity of different fibrillar Aβ species along the
walls of the blood vessels, being more evident for the Aβ1-40 and AβN3(pE) peptide
species. These vascular amyloid deposits are associated with structural vascular alterations
and phenotypic loss of pericytes, vessel-associated microglia, and astrocytic end-foot pro-
cesses. Interestingly, we observed in AD brains a loss in continuity of the TJs that constitutes
the BBB, as well as extensive caspase-5 immunoreactivity in the cerebral vasculature.
The presence of AβN3(pE) deposits in the cerebral vasculature has been described
in several animal models of AD. However, their presence was not detected in brains with
sporadic AD [5] and transgenic mouse models [36,37]. The cerebrovascular deposits of
AβN3(pE) have been reported preferentially in familial AD [38]. However, we found
extensive fibrillar/insoluble vascular deposits of both truncated Aβ species and the full-
length Aβ species (Aβ1-40) in several sporadic AD cases. Recently, it has been proposed
that the balance of Aβ maturation in CAA and plaques defines distinct pathological
subgroups of Aβ amyloidosis, inclusive of AβN3(pE) [39].
Cerebrovascular amyloid accumulation could disrupt the NVU in AD patients and ex-
acerbate pathology [40]. Atrophy of pericytes, swelling of the astrocytic end-foot processes,
loss of perivascular plexus, decrease in vascular smooth muscle actin, and accumulation of
laminin in basement membranes have all been observed in AD brains [41]. Accordingly,
we detected a loss of the cellular NVU components, but this event was associated with
the vascular amyloid fibrillar deposits. Nevertheless, the mechanisms by which fibril-
lar Aβ could aggregate in the vasculature and go on to cause NVU damage in AD are
not yet clear. First, it has been proposed that microvascular amyloid seeds could recruit
wild-type Aβ peptides and promote their assembly into amyloid fibrils, in a prion-like
way, triggering cytotoxicity [22]. Second, the altered expression of some molecules and
receptors (RAGE and LRP1 receptors at the BBB; Aβ chaperone proteins, such as apoE
and apoJ; and possibly vascular-specific genes, such as mesenchyme homeobox gene 2
(MEOX2) and myocardin (MYOCD)) is associated with control of Aβ efflux and influx of
the brain[1]. The dysfunction of these molecules (Figure 7) leads to a decrease of brain
perfusion, due to a compromised interstitial fluid (ISF) drainage, resulting in a cerebral
blood flow (CBF) reduction by vascular Aβ accumulation [42]. This oligemia (Figure 7) is
reflected in a loss of oxygen and glucose, causing excitotoxicity and plasticity impairment,
and in an increase in anaerobic brain metabolism [43]. Therefore, oligemia could alter
the pH, electrolyte balances, and water gradients, leading to the development of edema,
white matter lesions, and glutamate accumulation. Likewise, it could also trigger a loss
of neuronal and BBB glucose receptors (GLUT1 and GLUT3, respectively) that can lead
to tau phosphorylation [41], probably through the mitogen-activated protein kinase path-
way [44] (Figure 7). Conversely, tau deposition is generally not a prominent feature of CAA
pathology, but it has been observed around Aβ-laden vessels in sporadic and hereditary
CAA [45]. It has been suggested that tau could induce leukocyte trafficking into the brain
in vivo in a transgenic animal model and functional damage to brain endothelial cells in
an in vitro BBB model [41]. In this study, we observed pathological tau surrounding the
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cerebral vessels, which could trigger the previously mentioned effects. All of these events
could contribute to alteration in the NVU and neuronal death [40]. We also observed
different effects associated with oligemia and amyloid angiopathy, such as string vessels,
vascular structural change, irregularities in the capillary surface, and BBB discontinuity.
String vessels may form as a result of endothelial cell death, followed by the collapse of the
capillary walls, leaving only remnants of the extracellular matrix caused by a decrease of
CBF; they are not functional in maintaining BBB integrity [42]. It has been suggested that
Aβ accumulates substantially along string vessels [46]. In support of this hypothesis, we
observed that string vessels are associated with fibrillar Aβ vascular deposits. Interestingly,
we only observed this event with the vascular deposits of the AβN3(pE) peptide.
Several studies have reported that focal vascular regression and decreased microvas-
cular density occur in AD [47,48]. On the other hand, the low levels of MEOX2 specifically
found in brain endothelial cells isolated from AD patients have been shown to mediate
aberrant angiogenic responses of human brain endothelium to angiogenic factors, such as
vascular endothelial growth factor (VEGF), both in vivo and in vitro, leading to premature
capillary pruning [48]. This effect was associated with areas close to fibrillar amyloid
plaques. Hence, we noticed that fibrillar amyloid plaques were also related to BBB discon-
tinuity and also presumptively with its breakdown (Figure 7). It has been demonstrated
that the exposure to oligomeric forms of Aβ significantly decrease levels of occludin, Cl-5,
and ZO-1, and compromises BBB integrity [49,50]. The decrease in TJ proteins might be
partly explained by the vascular-associated matrix metalloproteinase-9 (MMP-9; Figure 7)
activity, because TJ proteins and basement membrane are substrates for this enzyme [51].
Future experiments are necessary to determine if diffuse or fibrillar amyloid plaques are
likely to trigger BBB rupture, in addition to vascular amyloid deposits.
On the other hand, the oligomeric theory has gained interest in recent years, where
it has been postulated that Aβ oligomers, rather than fibrils, can cause several cellular
toxic effects and trigger neuronal death [11]. This hypothesis has been supported by the
findings from a number of studies. It has been shown that Aβ oligomers can cause damage
and increased permeability of the neuronal lipid bilayer, alter calcium homeostasis, and
favor the neuroinflammatory response, all of which are events not associated with Aβ
fibrils [52–56]. In this study, we observed a pathological effect of Aβ fibrillar on the cells
that constitute the NVU. However, as the NVU cells present several receptors for the Aβ
oligomers [57], it is possible that these could trigger the first toxic events with insoluble
amyloid deposits leading to the later degeneration of these cells in AD brains.
Nevertheless, the mechanisms by which fibrillar Aβ could bind to cells of the NVU
and consequently cause degeneration are not yet clear. Exposure of microglia to fibrillary
Aβ in vitro leads to activation and production of chemokines, cytotoxic cytokines [58]
and reactive oxygen species (ROS)[59,60], which could lead to neuronal toxicity and
degeneration [61] (Figure 7). It has been suggested that, in healthy brains, microglial
cells are in “resting” state, characterized by small-bodied cells with long, finely branched
processes. In contrast, under pathological conditions, microglia are in an “active” amoeboid
shape in which they have begun to swell and retract their processes, or may have completely
lost them. Interestingly, we found that microglial cells surrounding amyloid plaques have
amoeboid-like morphology but also exhibit nuclear condensation suggesting that they
are entering an apoptotic process. We also observed that the microglia that surround the
NFT have a resting morphology, while those that surround the cells with intracellular
deposits of Aβ have an amoeboid shape, suggesting that intracellular Aβ deposits may be
associated with the activation of these cells.
It is believed that microglia, the major phagocytic cells in the brain, are part of the
first step in degrading soluble and fibrillar Aβ through Scavenger Receptors (SRs) [62].
There are many of these receptors that trigger activation of signaling cascades and these
are depicted in the schematic in Figure 7.
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Figure 7. The hypothesis of neurovascular unit (NVU) alteration triggered by Aβ fibrillary deposits.
(A) Aβ monomers are incorporated into oligomers and fibrils in the brain, triggering NVU degenera-
tion. Some endothelial receptors such as the receptor for advanced glycation end-products (RAGE)
and low-density lipoprotein receptor-related protein 1 (LRP1) are involved in the vascular Aβ accu-
mulation and thus with blood–brain barrier (BBB) damage. The microglial receptors TLR2, MARCO,
SCARA 12 , CR3 (β2 integrin), CR4, SCARB2, CD36, TLR4-TLR6, CD47, α6β1 integrin, SR-A1, and
TREM 2 interact with fibrillar Aβ. Subsequently, microglia and astrocytes secrete pro-inflammatory
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molecules that promote neuronal and vascular damage. Fibrillar Aβ aggregates or NP could trigger
the breaking of tight junctions specifically by metalloproteinase 9 (MMP9). (B) There is an accumula-
tion of fibrillar Aβ in endothelial cells causing oligemia (decrease in oxygen and glucose levels). In
the neuron, there are two important glucose receptors GLUT 1 and GLUT 3, which are decreased
during Alzheimer’s disease, leading to phosphorylation of tau, excitotoxicity, and cell death. Various
studies have found a decrease in aquaporin 4 (AQ4) in astrocytes, generating edema of the astrocytic
feet. The pericytes undergo dilation by relaxation due to the presence of PGE 2. The neurotransmitter
glutamate is released from the neuron to the astrocyte, where it produces an increase in intracellular
calcium. We rely on the genome.jp/keg and expasy.org platforms and the results obtained in this
study for the proposed hypothesis.
Caspases are cysteine-dependent aspartate-directed proteases. Caspases are funda-
mentally involved in apoptosis and inflammation. Previous studies support the notion
that caspase-mediated cleavage of critical proteins contributes to neurodegeneration in
AD [63]. Caspases could trigger Aβ levels during apoptosis. Furthermore, Aβ could
initiate apoptosis, which in turn would increase caspase activity. Some caspases have
been described in AD. Expression of caspase-3 has been reported in AD cases, where it is
co-localized with NFTs and NPs in the brain [64]. Activated caspase-3 immunoreactivity
was also found to be present in a large subset of neurons, blood vessels, and glial cells.
Caspase-6 [63] has been described in degenerating neurons and neurites of AD but not in
control brains [63]. In this study, for the first time, we describe the expression of activated
caspase-5 throughout the cerebral vasculature of AD brains. Caspase-5 was not evident
in the brains from healthy individuals. It has been shown that caspase-5 has been related
to apoptosis, inflammation, proliferation, and that its expression, activation and catalytic
activity are inducible by proinflammatory agents, such as IL-1β, TNF-α, and LPS in Human
Retinal Pigment Epithelial Cells [65,66]. Future studies will be required to determine the
role of caspase-5 in cerebral vessels and its specific relationship with Aβ and NFTs in AD.
As with vessel-associated microglia, astrocytic end-foot processes could limit the
disease in the early stages. As the amyloid vascular pathology progresses, it could trigger
molecular alterations and even degeneration. It has been suggested that astrocytes can
bind to fibrillar Aβ via CD36, CD47, RAGE, ApoE, α7nAChR, and glycoprotein recep-
tors. Although the most common pathway is through RAGE and the NF-kB pathway,
increased expression of TNF- α, IL-1 β, COX2, and other cytokines [67] may also promote
a neuroinflammatory environment (Figure 7). As a consequence, the BBB structure and ex-
pression/distribution of tight junctions are altered [68]. Moreover, in the temporal cortex of
AD patients, reduced mRNA expression of the water channel aquaporin 4 (AQP4; Figure 7)
and activated astrocyte marker glial fibrillary acidic protein (GFAP) in association with
the severity of CAA pathology [69] and in AD-related pathology, including Aβ burden
and Braak stage [70]. In our study, we noticed that vascular amyloid deposits altered the
end-foot processes morphology. We observed that the amyloid fibrillar deposits caused
thinning of these terminations, in comparison with the diffuse Aβ deposits or the control
brains. These events could reflect cellular degeneration and death. The astrocytic end- foot
dysfunction during AD may exacerbate Aβ accumulation by disturbing cerebrovascular
Aβ clearance, along with the ISF drainage via the glymphatic systems [71], influencing
arteriolar tone by a steady low-level efflux of prostaglandin-E2 (PGE2) as a result of basal
[Ca2+] intracellular fluctuations [72]. This is consistent with an assumption that astrocyte
dysfunction is key to the breakdown of neurovascular coupling [40].
Both astrocytes and microglia could promote endothelial autophagy of the endothelial
cells by activation of AKT and PI3K signaling [73]. Additionally, it has been described that
high concentrations of Aβ induce mitochondria dysfunction, DNA fragmentation, and
notorious endothelial cell death [74]. For instance, it has been suggested that Aβ-induced
apoptosis in vascular cells via death receptors (DRs). DR4 and DR5, as key players in CAA
cell dysfunction [75], could trigger mitochondrial dysfunction and activation of caspase 8,
and then caspase 3, resulting in protein cleavage and further apoptosis (Pereira et al. 2004).
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Finally, it has been proposed that degeneration of pericytes could be a pathophysio-
logical key to NVU dysfunction in AD [76–78]. In post-mortem studies, an accumulation
of blood-derived proteins (including fibrinogen, thrombin, plasminogen, immunoglobulin
G, and albumin) has been found in the hippocampus and cortex of AD subjects, and this
is associated with pericyte degeneration [77]. Pericyte degeneration in AD may further
exacerbate parenchymal and vascular Aβ accumulation [78]. Furthermore, degenerating
pericytes could trigger BBB breakdown, CBF reductions, and hypoxia, which, in turn, initi-
ates age-dependent secondary neuronal and synaptic changes associated with neuronal
and synaptic dysfunction [76]. In this study, we observed strong immunoreactivity of
contractile pericytes in AD brains.
4. Materials and Methods
4.1. Brain Tissue
Human brain tissue was obtained from the National Dementia BioBank, Mexico,
following the institutional bioethics guidelines. Tissues from six sporadic AD (age range 65
to 90 years, disease duration 10–15 years, and 3–6 h postmortem delay) and six cognitively
normal patients (age range 65 to 90 years, and 3–6 h postmortem delay) were used. The
diagnosis of AD followed the National Institute of Neurological and Communicative
Disorders and Stroke—Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA)criteria [79]. AD tissue with stages IV–VI (according to Braak’s staging system)
was used. Braak IV–VI is associated with a high degree of CAA [39]. Control cases were
defined by the absence of amyloid plaques, including cases with primary age-related
tauopathy and CAA [39].
4.2. Immunofluorescent Staining
Blocks of temporal cortex from AD (n = 6) and control (n = 6) brains were fixed by
immersion in a solution of 4% paraformaldehyde in phosphate-buffered saline (PBS), pH
7.4, at 4 ◦C. Sections of 50 µm in thickness were cut on a sliding microtome (Jung His-
toslide 2000R; Leica, Heidelberg, Germany). Antibody epitopes were retrieved, following
treatment in citrate buffer (0.1 M citric acid, 0.1 M sodium citrate, pH 6.0) at 100 ◦C, for
15 min. Tissues designated to assess Aβ were incubated with 70% formic acid, for 20 min,
at room temperature. Non-specific sites were blocked with 0.2% IgG-free albumin (Sigma-
Aldrich, St. Louis, MO, USA) in PBS, for 1 h, at room temperature. Tissues were then
incubated with the primary antibodies cocktail (Table 1), overnight, at 4 ◦C, and then with
the secondary antibodies for 1 h (Table 2). Sections were counterstained with thiazine red
(TR), to identify beta-pleated sheet conformation [12], and with TO-PRO®-3 or DAPI for
staining nuclei. Slices were mounted in Vectashield antifade mounting medium (Vector
Laboratories, Burlingame, CA, USA).
4.3. Immunofluorescent Staining for Tight Junctions
Fresh-frozen temporal cortex tissues were obtained from AD (n = 3) and control
(n = 3) individuals. Tissue was cryopreserved in OCT (optimal cutting temperature)
compound (Sakura Finetek, Torrance, CA, USA), and 50-µm sections were cut, using a
cryostat (Leica, Nussloch, Germany). Slices were fixed with paraformaldehyde, at room
temperature, for 20 min, and permeabilized with 100% methanol, at −20 ◦C, for 20 min.
From this step, a brain-slice chamber system maintained the brain-slice preparations in a
constantly humid environment. Non-specific sites were blocked with 1% bovine serum
albumin (BSA) (Sigma-Aldrich, St. Louis, MO, USA), in PBS, for 1 h, at room temperature.
Lipofuscin autofluorescence was removed with Sudan B Black (SBB) solution (0.1% SBB in
70% ethanol) for 10 min. Tissues were incubated with the rabbit polyclonal anti claudin-5
antibody (1:300; Abcam; Cambridge, UK), overnight, at 4 ◦C, and then with FITC-tagged
goat–anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 1 h,
at room temperature. Sections were counterstained with TO-PRO®-3 or DAPI. Slices were
mounted in Vectashield antifade mounting medium (Vector Laboratories).
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Table 1. List of primary antibodies used in this study.
Primary Antibody Protein and Epitope Species; Isotype Dilution Reference
AβN3(pE) Aβ peptide bearing N-terminalpyroglutamate at position 3 Mo. and Rb. 1:100 [6]
AβN11(pE) Aβ peptide bearing N-terminalpyroglutamate at position 11 Rb. 1:100 [6]
Aβ1-40 Synthetic Aβ1-40; N-terminal epitopewithin amino acid residues 1–12 Mo. 1:300 Sigma-Aldrich
Aβ1-42 Synthetic Aβ1-42; C-terminal epitopewithin amino acids 36–42 Rb. 1:200 Thermo-Scientific
Polyclonal anti α smooth
muscle actin (α-SMA)
N-terminus region of human alpha smooth
muscle actin Rb. 1:500 GeneTex
Ionized calcium-binding
adapter molecule 1 (Iba1)
Synthetic peptide within human Iba1 aa
1–100 (Cysteine residue). Rb. 1:1000 Wako
GFAP Glial fibrillary acidic protein Rb and Mo. 1:500 Thermo-Scientific
ALZ50 Amino acids: 5–15, 312–322Structural conformational change in tau Mo; IgM. 1:20 [80]
TG-3
Regional conformational change in tau
dependent on phosphorylation at Thr231
and Ser235
Mo.; IgM 1:40 [81]
Caspase-5 Activated caspase-5 resulting from cleavageadjacent to Ser331 Rb. 1:500 GeneTex
Mo = mouse; Rb = rabbit.















Double and triple-immunolabeled sections were examined with a confocal laser
scanning microscope (TCS-SP8, Leica, Heidelberg, Germany), using 20×, 40×, and a 100×
oil-immersion plan Apochromatic objective (NA 1.4). Ten to fifteen consecutive single
sections were sequentially and simultaneously scanned at 0.8–1.0 µm intervals, for two or
three channels throughout the z-axis of the sample. The collection of images was projected
and analyzed onto the two-dimensional plane, using pseudo-color display of green (FITC),
red (TRITC), and blue (CY5). Fluorochromes were excited at 488 nm (for FITC), 540 nm
(for TRITC), and 650 nm (for CY5).
5. Conclusions
Our results suggest that, in the late stage of AD, there are extensive vascular deposits
of fibrillar Aβ, containing both full-length and truncated Aβ species. Furthermore, these
insoluble vascular amyloid deposits were associated with a loss of cellular elements that
constitute the NVU and in a disruption of the BBB. The high caspase-5 immunoreactivity
found in the cerebral vasculature suggests that there is an inflammatory response or
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pyroptosis of cells that constitute the NVU. Therefore, further research must focus on
elucidating the pathological mechanisms involved in NVU dysfunction in AD brains,
including the role of different Aβ species and caspase-5. The functionality of the NVU
should be considered as a therapeutic target for AD.
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